CV Event Prediction, Risk Assessment in Type 2 Diabetes
The risk assessment method used in the SAVOR-53 TIMI trial provided a “practical, well-calibrated risk prediction tool.”
Among U.S. women, a normally high circulating prolactin concentration is associated with a reduced risk for type 2 diabetes.
Greater variation of fasting plasma glucose over time is associated with an increased risk of developing type 2 diabetes.
Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.